News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,603 Results
Type
Article (41342)
Company Profile (265)
Press Release (688980)
Multimedia
Podcasts (92)
Webinars (20)
Section
Business (204838)
Career Advice (2032)
Deals (35582)
Drug Delivery (128)
Drug Development (81512)
Employer Resources (173)
FDA (16507)
Job Trends (14981)
News (346812)
Policy (32750)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2595)
Accelerated approval (47)
Adcomms (26)
Allergies (171)
Alliances (49579)
ALS (210)
Alzheimer's disease (1793)
Antibody-drug conjugate (ADC) (442)
Approvals (16884)
Artificial intelligence (657)
Autoimmune disease (289)
Automation (56)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (220)
Biotechnology (175)
Bladder cancer (187)
Brain cancer (71)
Breast cancer (747)
Cancer (5785)
Cardiovascular disease (467)
Career advice (1724)
Career pathing (42)
CAR-T (330)
CDC (56)
Celiac Disease (3)
Cell therapy (895)
Cervical cancer (47)
Clinical research (70782)
Collaboration (2045)
Company closure (5)
Compensation (1388)
Complete response letters (79)
COVID-19 (2741)
CRISPR (107)
C-suite (1113)
Cystic fibrosis (152)
Data (7838)
Decentralized trials (3)
Denatured (27)
Depression (160)
Dermatology (86)
Diabetes (586)
Diagnostics (6924)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (316)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (283)
Earnings (92061)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119457)
Executive appointments (1077)
FDA (20213)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1715)
Gene editing (233)
Generative AI (56)
Gene therapy (718)
GLP-1 (1052)
Government (4729)
Grass and pollen (6)
Guidances (408)
Healthcare (18994)
HIV (79)
Huntington's disease (56)
IgA nephropathy (97)
Immunology and inflammation (287)
Immuno-oncology (92)
Indications (191)
Infectious disease (3078)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (288)
Interviews (319)
IPO (16667)
IRA (50)
Job creations (3647)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (99)
Layoffs (562)
Leadership (39)
Legal (7953)
Liver cancer (99)
Longevity (32)
Lung cancer (760)
Lymphoma (429)
Machine learning (60)
Management (59)
Manufacturing (1043)
MASH (185)
Medical device (13925)
Medtech (14046)
Mergers & acquisitions (20157)
Metabolic disorders (1493)
mRNA (204)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (412)
Neuropsychiatric disorders (105)
Neuroscience (3293)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4530)
Now hiring (78)
Obesity (698)
Opinion (286)
Ovarian cancer (218)
Pain (252)
Pancreatic cancer (299)
Parkinson's disease (358)
Partnered (33)
Patents (592)
Patient recruitment (667)
Peanut (62)
People (59563)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22066)
Phase 2 (31184)
Phase 3 (23205)
Pipeline (8661)
Policy (314)
Postmarket research (2568)
Preclinical (9404)
Press Release (64)
Prostate cancer (298)
Psychedelics (54)
Radiopharmaceuticals (320)
Rare diseases (1070)
Real estate (5969)
Recruiting (70)
Regulatory (25374)
Reports (56)
Research institute (2412)
Resumes & cover letters (353)
Rett syndrome (39)
RNA editing (21)
RSV (88)
Schizophrenia (176)
Series A (288)
Series B (212)
Service/supplier (11)
Sickle cell disease (112)
Special edition (23)
Spinal muscular atrophy (166)
Sponsored (48)
Startups (3639)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1088)
Venture capital (107)
Weight loss (450)
Women's health (125)
Worklife (20)
Date
Today (189)
Last 7 days (880)
Last 30 days (3605)
Last 365 days (30238)
2026 (12354)
2025 (30170)
2024 (35211)
2023 (40072)
2022 (51173)
2021 (55707)
2020 (54081)
2019 (46538)
2018 (35015)
2017 (32107)
2016 (31479)
2015 (37551)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (741)
Alabama (93)
Alaska (7)
Arizona (348)
Arkansas (14)
Asia (39660)
Australia (6502)
California (13238)
Canada (3759)
China (1332)
Colorado (566)
Connecticut (574)
Delaware (403)
Europe (85820)
Florida (1980)
Georgia (424)
Hawaii (3)
Idaho (62)
Illinois (1050)
India (90)
Indiana (598)
Iowa (23)
Japan (534)
Kansas (131)
Kentucky (50)
Louisiana (40)
Maine (76)
Maryland (1585)
Massachusetts (9434)
Michigan (362)
Minnesota (715)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (142)
New Hampshire (84)
New Jersey (3478)
New Mexico (29)
New York (3456)
North Carolina (1678)
North Dakota (9)
Northern California (6639)
Ohio (396)
Oklahoma (23)
Oregon (41)
Pennsylvania (2661)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5218)
Tennessee (210)
Texas (2098)
United States (46657)
Utah (393)
Vermont (1)
Virginia (321)
Washington D.C. (80)
Washington State (1056)
West Virginia (4)
Wisconsin (125)
Wyoming (2)
730,603 Results for "erasca inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pancreatic cancer
Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up
Fresh off a major clinical win, Revolution Medicines alleges that Erasca’s pancreatic cancer drug infringes on key patent protections and that the rival has “improperly compared” the companies’ assets publicly.
April 28, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Erasca Reports First Quarter 2026 Business Updates and Financial Results
May 12, 2026
·
12 min read
Press Releases
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
May 11, 2026
·
6 min read
Press Releases
Erasca to Present at Upcoming Conferences in February 2025
February 5, 2026
·
1 min read
Press Releases
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
March 10, 2026
·
7 min read
Press Releases
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
March 13, 2026
·
11 min read
Press Releases
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
March 5, 2026
·
7 min read
Press Releases
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
April 27, 2026
·
2 min read
Press Releases
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
April 28, 2026
·
13 min read
Press Releases
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
February 24, 2026
·
7 min read
1 of 73,061
Next
